Search Results for: lorenz studer

Lorenz Studer on Day 1 #ISSCR2018: HESC-based therapies for Parkinson’s Disease

GForce_Superhero_logo

One of the highlights of Day 1 of #ISSCR2018 for me so far was the talk by Lorenz Studer (Co-Founder of BlueRock) on the use of human embryonic stem cell (HESC)-derived dopamine neurons for Parkinson’s Disease. Note that for this post and if I have time any others on this meeting, they are probably going …

Lorenz Studer on Day 1 #ISSCR2018: HESC-based therapies for Parkinson’s Disease Read More »

Lorenz Studer named 2015 MacArthur Fellow for stem cell work

Lorenz-Studer

Congratulations to Lorenz Studer as a MacArthur Fellow. The annual selection of MacArthur Fellows highlights creative leaders in a variety of fields. The fellows receive $625,000 with no strings attached. Stem cell biologists have been selected on a regular basis over the years as MacArthur Fellows including Kevin Eggan (2006), Sally Temple (2008), and Yukiko …

Lorenz Studer named 2015 MacArthur Fellow for stem cell work Read More »

50 stem cell influencers on Twitter to follow in 2019

stem cells on Twitter, top-stem-cell-influencers-Twitter

Who are the top stem cell and regenerative medicine influencers to follow on Twitter and elsewhere in 2019? Terrapin asked this kind of broad question to some within our community about 5 years ago and came up with a Top 50 list of stem cell influencers, which I like to joke I was “at the top …

50 stem cell influencers on Twitter to follow in 2019 Read More »

Hope on Parkinson’s front: Japan IPSC trial 1st patient

Fig-3i-Kikuchi-et-al.-Nature-2017-IPS-cell-Parkinsons-

In Parkinson’s Disease patients develop neurological dysfunction as they lose a special kind of brain cell called dopaminergic (or dopamine) neurons. While a number of different approaches to this disease have been studied for decades, nothing has proven particularly successful in slowing its progression. As a result there has been a big need for novel thinking …

Hope on Parkinson’s front: Japan IPSC trial 1st patient Read More »

Ian Wilmut, who cloned Dolly, opens up about his Parkinson’s Disease

Ian-Wilmut

One of the most famous living biological scientists, Sir Ian Wilmut, just announced that he has Parkinson’s Disease. I wish him the best in dealing with this illness. Wilmut is very well-known for having cloned the first mammal, Dolly the Sheep. This work followed on the earlier breakthrough by Sir John Gurdon of cloning the …

Ian Wilmut, who cloned Dolly, opens up about his Parkinson’s Disease Read More »

Stem cell movers and shakers early 2018

stem-cell-movers-and-shakers

Today’s piece is a stem cell movers and shakers post about individuals who have gotten awards, made moves, or otherwise made news recently. In some cases I’ve included relevant embedded tweets announcing the news. In case you’re wondering, the image at right is my attempt last year to make a graphic design that reflect both …

Stem cell movers and shakers early 2018 Read More »

On the threshold of cell therapy for Parkinson’s disease

Dopamine-neurons-derived-from-a-Parkinsons-disease-patients-iPSCs-Tyrosine-hydroxylase-1

By Jeanne Loring There are ten million people in the world who have Parkinson’s disease. 125,000 of these are living in California.  People with the disease often have to step away from their jobs because the main symptoms – tremor or freezing up of muscles – make it difficult to get through a whole day …

On the threshold of cell therapy for Parkinson’s disease Read More »

How risky are stem cell trials for Parkinson’s beginning in China?

Brain-PET-scan

New human clinical trials using derivatives of pluripotent stem cells in China for Parkinson’s Disease (PD) have raised expectations and some eyebrows. PD is a neurodegenerative condition, sometimes diagnosed or followed by PET scans such as the one at left, characterized by loss of dopaminergic neurons leading to severe and sometimes life-threatening symptoms. Pluripotent stem …

How risky are stem cell trials for Parkinson’s beginning in China? Read More »